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Abstract 
Background: Human T-lymphotropic virus type 1 (HTLV-1) infects an estimated 10 million persons globally with 
transmission resulting in lifelong infection. Disease, linked to high proviral load, occurs in a minority. In established 
infection HTLV-1 replicates through infectious spread and clonal expansion of infected lymphocytes. Little is known 
about acute HTLV-1 infection. The kinetics of early HTLV-1 infection, following transplantation-acquired infection in 
three recipients from one HTLV-1 infected donor, is reported. The recipients were treated with two HTLV-1 enzyme 
inhibitors 3 weeks post exposure following the detection of HTLV-1 provirus at low level in each recipient. HTLV-1 
infection was serially monitored by serology, quantification of proviral load and HTLV-1 2LTR DNA circles and by 
HTLV-1 unique integration site analysis.
Results: HTLV-1 antibodies were first detected 16–39 days post-transplantation. HTLV-1 provirus was detected by 
PCR on day 16–23 and increased by 2–3 log by day 38–45 with a peak proviral doubling time of 1.4 days, after which 
steady state was reached. The rapid proviral load expansion was associated with high frequency of HTLV-1 2LTR DNA 
circles. The number of HTLV-1 unique integration sites was high compared with established HTLV-1 infection. Clonal 
expansion of infected cells was detected as early as day 37 with high initial oligoclonality index, consistent with early 
mitotic proliferation.
Conclusions: In recipients infected through organ transplantation HTLV-1 disseminated rapidly despite early anti-
HTLV-1 treatment. Proviral load set point was reached within 6 weeks. Seroconversion was not delayed. Unique inte-
gration site analysis and HTLV-1 2LTR DNA circles indicated early clonal expansion and high rate of infectious spread.
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Background
Human T-lymphotropic virus type-1 (HTLV-1) is associ-
ated with two main clinical disorders that arise in 5–8 % 
of carriers: HTLV-1 associated myelopathy (HAM), 
a progressive, inflammatory, spastic paraparesis, and 
adult T cell leukaemia/lymphoma (ATLL), an aggres-
sive malignancy of CD4+ T-lymphocytes. The majority 
of infection occurs through sexual intercourse or from 
mother-to-child during breast feeding but infection from 
unscreened blood transfusions or organ transplants can 
occur [1]. Little is known about early HTLV-1 infec-
tion, which is asymptomatic, but data from recipients of 
infected blood transfusions suggest that most serocon-
version occurs within 2 months [2]. Knowledge of the 
course of early HTLV-1 infection in immunosuppressed 
individuals is limited to case reports of HTLV-1-asso-
ciated disease following infection at the time of organ 
transplantation with infection usually not recognised 
until the onset of symptoms [3–12].
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Evidence from phylogenetic studies and integration 
site analysis reveals two routes by which HTLV-1 propa-
gates within the host [13–16]: infectious spread, where 
the virus spreads from cell-to-cell through the forma-
tion of a virological synapse between infected and unin-
fected CD4+ T-cells [17], resulting in integration of the 
HTLV-1 provirus in a new genomic location in the newly 
infected host cell; and mitotic proliferation of infected 
CD4+ T-lymphocytes, which gives rise to clonal popu-
lations of infected CD4+ cells that can be identified and 
quantified by their unique genomic integration site [16].
The relative contributions of infectious and mitotic 
spread at different time points of infection are not 
known; this knowledge is required for designing rational 
treatment protocols. HTLV-1 viral RNA is rarely found in 
human plasma [21, 22], which is not infectious [23]. In 
HIV infection, viral episomes containing two long termi-
nal repeats (2LTR DNA circles) are formed after comple-
tion of viral cDNA synthesis and translocation of the viral 
genome to the host cell nucleus, where recombination 
and direct ligation lead to the formation of episomes. For 
HIV there is evidence that these 2LTR DNA circles are a 
surrogate marker of ongoing viral replication [18–20] in 
the absence of detectable viral RNA. HTLV-1 2LTR DNA 
circles have not been studied previously.
Since late 2002, all blood donations in the UK have 
been screened for HTLV-1 [24] but real-time screen-
ing of organ donors only became universal in 2012, after 
the events reported here. We report the investigation 
and management of three transplant recipients exposed 
to HTLV-1 through solid organ transplantation from a 
single donor, which leads to new insights into the early 
spread of HTLV-1 infection in vivo.
Results
Clinical cases (Table 1)
The liver and both kidneys were retrieved from a 
deceased female Caucasian donor, who was not known to 
carry, and had no risk factors for, HTLV-1 infection. The 
organs were transplanted in accordance with UK Blood 
and Transplant service protocols to three HLA class-
matched male recipients. At the time of organ retrieval 
the donor HTLV status was reported as ‘awaited’ but 
after transplantation the HTLV-1 seropositive status of 
the donor was detected and confirmed, following which 
the recipients were informed. No suitable samples for 
quantifying the proviral load of the donor were available.
Clinical details of the recipients are summarised in 
Table  1. In one patient, the transplanted kidney was 
explanted within 12 h because of life-threatening haem-
orrhage (unconnected with the infection); the other 
kidney recipient developed allograft rejection and so 
underwent explantation. The liver recipient, treated with 
standard immunosuppression, remains well with normal 
graft function.
HTLV-1 infection was diagnosed by HTLV-1 DNA 
PCR in all three recipients who were then commenced on 
zidovudine and raltegravir, which inhibit HTLV-1 reverse 
transcriptase [25, 26] and integrase [27] respectively, with 
the aim of limiting early infectious spread. Antiretroviral 
Table 1 Clinical details of transplant recipients
b.d. Bis in die (twice a day), t.d.s. ter die sumendum (three times daily)
Case 1 Case 2 Case 3
Primary organ pathology Alcoholic liver disease Tubulo-interstitial nephritis with focal 
sclerosis
End stage renal failure of unknown 
aetiology (diabetes/hypertension)
Age at transplantation (years) 58 48 57
Ethnicity Caucasian Black Caribbean Indian
Organ transplanted Liver Kidney Kidney
Class 1 HLA type A01, A24, B08, B15, C03, C07
DR1, DR3 DQ2, DQ5
A3, A34, B51, B71, Cw3, Cw16,
DR13, DQ7
A3, A24; B52, B55; Cw1, Cw12;
DR10 DR14; DQ5
Peri-operative immune suppression Basiliximab
Methylprednisolone
Basiliximab
Methylprednisolone
Basiliximab
Mycophenolate, Tacrolimus
Post operative immune suppression Mycophenolate, tacrolimus None Tacrolimus, prednisolone
Day post transplant antiretrovirals com-
menced
Day 19 Day 17 Day 26
Dose of antiretrovirals Zidovudine 250 mg bd
Raltegravir 400 mg bd
Zidovudine 100 mg tds
Raltegravir 400 mg bd
Zidovudine 100 mg tds
Raltegravir 400 mg bd
Day antiretrovirals stopped Day 66 Day 43 Day 80
Day organ removed Not applicable Day 0 Day 48
Indication for organ removal Not applicable Life-threatening intra-operative  
haemorrhage
Rejection/failure
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treatment, given for 24–54 days, was tolerated well by all 
recipients who, at 30 months post-transplantation, have 
no evidence of HTLV-1-associated disease.
HTLV‑1 seroconversion (Fig. 1)
In case 1 the first detection of anti-HTLV-1 antibodies 
was 16  days post-transplantation. The enzyme linked 
immunoassay (EIA) sample/cut-off (S/CO) optical den-
sity was 6.88 and faint bands indicative of antibodies to 
p24 (gag), rgp46-1 (env) and anti-GD21 (env) were seen 
on the western blot (Fig.  1, lane 5). Anti-p19 (gag) was 
first detected at day 32 (Fig.  1, lane 6). In case 2 anti-
HTLV-1 antibodies were first detected on day 39 (S/CO 
13.5) at which time the western blot revealed a strong 
response to GD21 and p19 with faint anti-p24 (Fig.  1, 
lane 15). Anti-rgp46-1 was detected at day 95 (Fig.  1, 
lane16). In case 3 although anti-HTLV-1 antibodies were 
detected by EIA at Day 16 (S/CO 1.88) this could not 
be confirmed by western blotting until anti-GD21 was 
first faintly detected on day 75 (Fig.  1 lane 23). Strong 
responses to GD21, p19 and p24 were present by day 145 
and a faint anti-rgp46-1 band at day 208 (Fig. 1 lanes 24, 
25).
HTLV‑1 long terminal repeat (LTR) sequence identity
Alignment of 442 nucleotides of the HTLV-1 5′LTR 
showed 100  % sequence identity between the three 
individuals, consistent with a common viral source of 
infection.
HTLV‑1 proviral load and doubling time (Fig. 2)
At 16  days post-transplantation HTLV-1 provirus could 
not be detected by quantitative PCR (qPCR) in any of the 
recipients (<0.01  % PBMC infected). However, by nested 
PCR provirus was detectable and estimated at 0.003  % 
PBMC in Case 1 (liver transplant) and at 0.01 % in Case 
2 (kidney transplant) but remained undetectable in Case 3 
(kidney transplant) until day 23 when it became detectable 
Fig. 1 Western blots (Genelabs HTLV 2.4) of antibodies to natural and recombinant HTLV-1 antibodies. To assist with interpretation, only relevant 
HTLV-1/2 antigens have been highlighted. GD21 is a recombinant p21 transmembrane envelope protein; rgp46-1 and rgp46-2 are recombinant 
gp46 surface proteins specific for HTLV-1 and HTLV-2, respectively. p19 and p24 are group antigens (gag) from the nucleus. HTLV-1 positive control 
shown in lanes 1 and 4, HTLV-2 positive control in lane 2, negative control in lane 3. Case 1 (lanes 5–13) days 16, 32, 46, 71, 74, 186, 214, 242 and 270 
post transplantation, shown in sequence. Case 2 (lanes 14–18) days 16, 39, 95, 136 and 254 post transplantation, shown in sequence. Case 3 (lanes 
19–25) days.16, 23, 30, 37, 75, 145 and 208 post transplantation, shown in sequence
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Fig. 2 Time courses for case 1 (upper panel), case 2 (middle panel) and case 3 (lower panel) indicating the period of immunosuppressive (Immune 
Supp.) and antiretroviral therapy (ART) in relation to transplantation (black arrow), HTLV-1 seroconversion (first red arrow—first detection of anti-
HTLV-1 Ab; second red arrow—all anti-HTLV-1 ab essential to confirm and type infection detected), HTLV-1 proviral load and frequency of HTLV-1 
2LTR DNA circles per 100 HTLV-1 infected cells
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at 0.01 % by qPCR. HTLV-1 proviral load increased in each 
case by 2–3 logs between days 16–23 and days 38–45, after 
which a steady state was reached with about 1 % PBMCs 
infected. Since it is known that there is a single copy of 
HTLV-1 integrated into each infected cell [28], the proviral 
load between the early time points can be used to estimate 
the doubling time of HTLV-1 infected CD4+ T-lympho-
cytes in the first month following infection which at its 
peak was a median of 1.43 days (range 1.1–2.9 days). The 
absolute lymphocyte count remained in the low normal 
range during this period (data not shown).
HTLV‑1 2LTR DNA circles (Fig. 2)
In case 1: 2LTR DNA circles were measured at five time 
points (days 16, 31, 45, 72 and 182). They were unde-
tectable at day 16, peaked at day 31 (4.2  ×  10−5 2LTR 
DNA circles/infected cell) and plateaued from day 45 
(3.6 × 10−6 2LTR DNA circles/infected cell).
In case 2: 2LTR DNA circles were measured at four 
time points (days 16, 38, 93 and 133). They were unde-
tectable at day 16, peaked at day 38 (0.21 2LTR DNA cir-
cles/infected cell) and declined by the next time point at 
day 93 (3.3 × 10−3 2LTR DNA circles/infected cell) and 
continued to decline (day 133, 3.6 × 10−4 2LTR DNA cir-
cles/infected cell).
In case 3: 2LTR DNA circles were measured at seven 
time points (days 16, 23, 29, 36, 50, 77 and 142) and were 
undetectable at day 16, with an initial peak at day 36 
(3.3 ×  10−3 2LTR DNA circles/infected cell) which had 
declined by next time point (day 50, 8.3  ×  10−4 2LTR 
DNA circles/infected cell) followed by a second peak at 
day 142 (0.16 2LTR DNA circles/infected cell) coinciding 
with a peak in the proviral load.
In all three cases, longitudinal analysis shows that the 
frequency of 2LTR DNA circles peaked between days 
31 and 38 post-transplant at the same time as the initial 
peak in proviral load and whilst the patients were taking 
HTLV-1 reverse transcriptase and integrase inhibitors. 
The reduction in frequency of 2LTR DNA circles thereaf-
ter was greater than the reduction in proviral load (Fig. 2).
Unique integration site (UIS) analysis (Fig. 3)
Each clone of infected cells can be defined by a unique 
genomic integration site [28] and the relative abundance, 
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Fig. 3  a shows the relative abundance of unique integration sites in each case at specified time points post transplantation (p.t.). b shows the 
change in absolute size of the 3–5 largest clones for each subject. c shows the oligoclonality index and the total number of unique integration sites 
for each subject over time
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or proportion of the proviral load contributed by each 
clone, is represented by the size of the respective sector in 
a pie chart (Panel A). The five most abundant integration 
sites at the early time points are colour-coded and can 
be tracked over time with regard to absolute abundance 
(Panel B). At the earliest available time points HTLV-1 
proviral load was too low to undertake high-throughput 
sequencing (HTS). HTS revealed that no integration site 
was found in more than one recipient, indicating that 
the observed integration sites were not persistent donor 
lymphocytes.
In Case 1 the degree of oligoclonal proliferation, meas-
ured by the oligoclonality index [16], peaked at day 59 
and then plateaued, while the number of UIS slowly 
increased (Panel C). The absolute abundance of HTLV-
1-infected clones was low compared with chronic infec-
tion acquired either from mother-to-child transmission 
or through sexual intercourse [16]. In both relative and 
absolute abundance clones present at day 61 were of 
lower abundance if redetected at day 186.
Case 2: At the first time point a large number of UIS 
(1031) were detected and the oligoclonality index was 
high; both these parameters subsequently decreased 
(Panel C). In this case the peak proviral load may be 
attributed to both an increase in the absolute number of 
integration sites (suggesting infectious spread) and vigor-
ous expansion of a small number of clones.
Case 3: The oligoclonality index, reflecting clonal pro-
liferation, peaked at day 48 and then declined over the 
next 3 months, with an increase in the absolute number 
of UIS consistent with infectious spread (Panel C).
Estimated number of clones
The number of clones was estimated from the integra-
tion site high throughput sequencing data using a newly 
developed and published method, DivE. DivE com-
pares multiple mathematical models fitted to rarefac-
tion curves, which give the expected number of infected 
clones as a function of the number of infected cells. The 
estimated number of clones (median 1.3 × 105) in these 
transplant recipients was substantially higher than those 
previously obtained in asymptomatic carriers (median 
9.0 ×  103) [28], patients with HAM (median 2.8 ×  104) 
[29], and patients ATLL with (median 1.7 × 103) [30].
Discussion
For the majority of individuals, HTLV-1 is transmitted 
from mother-to-child via breast feeding and as such it is 
nearly impossible to conduct a study during acute infec-
tion. This report of an unfortunate clinical event has pro-
vided a rare opportunity to quantify the kinetics of acute 
HTLV-1 infection. We report that anti-HTLV-1 anti-
body responses were not delayed by immunosuppressive 
therapy: Anti-HTLV antibodies were detected in two 
cases at the first available time point (day 16) and in the 
third by day 39. This is similar to reports from recipients 
of HTLV-1-infected blood transfusions, in whom the 
seroconversion window has been estimated at 55  days 
[31], with 50 % having detectable HTLV-1 antibodies by 
day 40 [2], and contrasts with the recent report of delayed 
seroconversion in transplant recipients [4] .
We report that HTLV-1 spread early and rapidly in the 
three transplant recipients. In established HTLV-1 infec-
tion the proviral load varies more than 5 logs between 
individuals, and a high proviral load predicts and pre-
dates HTLV-1-associated disease. Proviral load remains 
stable within an individual over many years [32–34] but 
it has not been established how early this proviral load 
‘set-point’ is reached. In the three recipients described 
here, who were immunosuppressed to different degrees, 
the ‘set-point’ proviral load was established by day 32–36 
post-exposure after a rapid increase in proviral load with 
a median peak proviral doubling time of 1.4 days.
Early HTLV-1 spread is both ‘infectious’ and ‘mitotic’. 
We observed that the HTLV-1 2LTR DNA circles peaked 
with the peak proviral load, and both declined by the next 
testing time point. 2LTR DNA circles have not been pre-
viously reported in HTLV-1 infection and thus there are 
no data on the survival of such episomal viral DNA in 
HTLV-1 infection. The assumption that these 2LTR DNA 
circles are markers of recent infection is based upon this 
phenomenon in HIV [18]. Here, we provide evidence in 
HTLV-1 infection that 2LTR DNA circles are detected, 
and that they, or the cells in which they exist, are rela-
tively short lived being much less frequent, as a propor-
tion of infected cells, 2 weeks after the peak. The peak of 
2 LTR DNA circles was observed after the introduction of 
oral antiretroviral therapy and there are two explanations 
for this: Firstly, whilst raltegravir has been demonstrated 
to prevent HTLV-1 spread from infected to uninfected 
cells in vitro [27], the therapy may not be active in vivo, 
even in primary infection due to reduced viral suscepti-
bility. Secondly, early infectious spread may have already 
occurred, prior to the introduction of antiretroviral ther-
apy, in a reservoir of inaccessible lymphoid tissue with 
later ‘spill over’ into the peripheral blood.
In each case, the peak oligoclonality index also coin-
cided with the peak proviral load. The oligoclonality 
index reflects the degree of mitotic proliferation, which 
in case 2 at day 39 (Fig.  3, panel A) scored >0.8, in the 
range normally observed in ATLL. In each case, the oli-
goclonality index then decreased and stabilised in the 
range observed in chronic asymptomatic infection (0.3–
0.55). The peak in the oligoclonality index also coincided 
with the peak frequency of 2LTR DNA circles. These 
results demonstrate both the expected early infectious 
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spread and unexpected profound early mitotic prolifera-
tion which subsequently diminished.
It is unclear whether the therapeutic immune suppres-
sion during transplantation allowed rapid expansion of 
particular clones, which subsequently reduced in both 
absolute and relative abundance, or whether the period 
of antiretroviral therapy altered the balance between 
infectious spread and mitotic proliferation. Antiretrovi-
ral therapy was delivered by day 23 post-transplantation 
at therapeutically relevant doses but appeared unable to 
inhibit the early infectious spread of HTLV-1. In both 
in vitro [35, 36] and in vivo studies [25], zidovudine has 
previously been shown to effectively inhibit HTLV-1 
infection. Similarly, raltegravir has also shown effective-
ness in vitro [27]. The usefulness of these drugs in humans 
in early infection has never before been tested but these 
aforementioned studies provided the rational for their 
use here. It is possible that the effectiveness of these 
drugs in vitro and in animal models does not translate to 
humans or, as we believe more likely, that drug treatment 
was initiated after its potential therapeutic window.
In this setting, treatment with zidovudine and ralte-
gravir did not control early infectious spread of HTLV-
1. Since donor infection was diagnosed too late for 
post-exposure prophylaxis, antiretroviral therapy was 
initiated with the intention of limiting infectious spread 
during the most intense phase of immune suppression. 
The data suggest that the treatment started between day 
16 and day 23 post-infection had no impact upon infec-
tious spread and therefore once HTLV-1 proviral loads 
exceeded 1 % this treatment was discontinued. However, 
these results do not exclude a possible benefit of earlier 
post or peri-exposure prophylaxis.
Early onset and rapid progression of HAM, as previ-
ously reported [5, 6] was not observed. Further data 
are required on the long-term outcome of recipients of 
HTLV-1-infected organ transplants because in the con-
text of an urgent life-saving transplant, such as liver or 
heart, the balance of risk and benefit may favour trans-
plantation, even from a HTLV-1 infected donor.
Conclusions
Following transplant-acquired infection: serological and 
molecular evidence of HTLV-1 can be detected as early 
as Day 16; the proviral set point is reached within 6 weeks 
and is the consequence of both mitotic and infectious 
spread; and there is no evidence that HTLV-1 enzyme 
inhibitors given from Day 16 of infection impact on the 
final proviral load.
Methods
Relevant clinical details were abstracted from the 
medical records of each patient. In each case 8–11 
sequential blood samples were obtained from day 16 
until 21 months post-transplantation.
Antibody detection
HTLV-1 antibodies were detected by Murex HTLV I + II 
(Diasorin Ltd, Dartford, UK) and confirmed by West-
ern blot using Genelabs Diagnostics® HTLV 2.4 assay 
(Genelabs, Redwood City, CA, USA) according to the 
manufacturer’s protocols.
HTLV‑1 proviral load
HTLV-1 proviral load was quantified by quantitative 
PCR (qPCR) as previously reported [32] with primers to 
the proviral tax and human β-globin gene, assuming one 
copy of tax [23] and two copies of β-globin per infected 
cell. Samples with unquantifiable provirus by qPCR (pro-
viral load <0.01  % PBMCs) were amplified by nested 
PCR (nPCR) to confirm presence of provirus. The peak 
doubling time (T2) for proviral HTLV-1 was estimated 
from the sequential data as follows and a median result 
calculated:
where V1 and V2 are the proviral loads at the first and 
second time-points, respectively and T is the time 
between measurements.
HTLV‑1 long terminal repeat (LTR) sequencing
To identify the genotype of the HTLV-1 provirus, we 
amplified a 523 bp fragment between the LTR (5′-CTCGC 
ATCTCTCCTTCACG-3′) and the gag gene (5′ CTGGTG 
GAAATCGTAACTGGA-3′). Cycling conditions: 98  °C 
for 3 min, 35 cycles 98 °C for 10 s, 64 °C for 20 s, 72 °C 
for 20 s followed by 72 °C for 10 min. The PCR products 
were electrophoresed on a 2 % agarose gel, inspected for 
length, and sequenced by Sanger sequencing.
HTLV‑1 2LTR DNA circles
PCR primers (Sigma, Poole, UK) for detection of unin-
tegrated HTLV-1 2LTR DNA circles were designed 
by alignment with the AKT strain of the complete 
HTLV-1 genome (Accession Number J02029.1 available 
at http://www.ncbi.nlm.nih.gov/nuccore/J02029.1) whilst 
the NCBI Blast database program was used to confirm 
specificity. Primer sequences were as follows: outer-pX-
forward: 5′-ATGAGCCCCAAATATCCCCCGGGG-3′, 
outer-pX-reverse: 5′-TCGATCTGTAACGGCGCAGAA 
C-3′, nested-pX-forward: 5′-AGC-
C A C C G G G A A C C A C C 
CAT-3′, nested-gag-reverse: 5′-GACAAAGGCCCGGT 
CTCGACCT-3′. Classical PCR: sample DNA isolated 
from a known number of cells was amplified in 50  μl 
T2 =
T
Log (V2/V1)/log 0.5
,
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reaction volumes containing 0.1  µM of each outer 
primer, 200 μM dNTPs, 2 mM MgCl2, 1× green GoTaq 
reaction buffer (Promega, Southampton, UK) and 1.25u 
GoTaq DNA polymerase (Promega). Cycling conditions 
on an MJ Research PTC-225 (Bio-Rad, Hemel-Hemp-
stead, UK) were: denaturation step 5  min at 94  °C, fol-
lowed by 35 cycles of amplification consisting of 1 min at 
95 °C, 30 s at 66 °C and 2 min at 72 °C, and a final elon-
gation step of a further 5 min at 72 °C. For nested PCR, 
1 µl of classical PCR product was transferred to 49 μl of 
reaction mix containing nested primers. Thermocycling 
conditions were: 94  °C for 5  min followed by 35 cycles 
consisting of 1 min at 95 °C, 30 s at 68 °C and 2 min at 
72  °C, and a 5 min final elongation step at 72  °C. 10 µl 
of each reaction was separated on 2 % agarose gels con-
taining 0.1 µg/ml ethidium bromide (Sigma) and visual-
ised under UV light. LTR DNA circles were determined 
by serial dilution of purified sample DNA in water and 
amplification of quadruplicates at each dilution. LTR cir-
cle quantity was determined using Poisson’s distribution, 
where load = −logn Fox dilution, and Fo is the number 
of negative tests/the number of tests. MT2 cells served 
as positive controls, DNA from HTLV-1 negative donor 
blood mononuclear cells and water as negative controls. 
2LTR DNA circle frequency was calculated as the abso-
lute number of 2LTR DNA circles per infected cell.
Clonal abundance of Integration sites by high throughput 
sequencing (HTS)
A customised HTS protocol to map and accurately quan-
tify proviral integration sites was used as previously 
described [16]. Fifty base-pair paired-end reads were 
acquired on an Illumina HiSeq 2000 analyser and the rel-
ative and absolute abundance of each clone deduced.
Estimation of oligoclonality index (OCI)
As previously described, the OCI calculates the disper-
sion of a clonal population, describing the contribution 
of the largest clones to the total proviral load. An OCI 
close to 0 suggests a polyclonal population, where each 
clone occupies an equal share of the proviral load, whilst 
an OCI close to 1 suggests a dominant single clone [16].
Diversity estimator (DivE)
DivE fits multiple mathematical models to nested sub-
samples of rarefaction curves, which depict the number 
of HTLV-1 infected clones against the number of HTLV-1 
infected cells. Model performance is assessed by measur-
ing the extent to which full data can be estimated from 
subsamples. Clonal diversity is estimated by extrapolat-
ing the best-performing models to a given population 
size (here the number of HTLV-1 infected cells in the 
circulation) [29]. A PBMC count of 3 × 109/L was assumed 
in estimating the number of HTLV-1 infected cells.
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